[April 23, 2014] |
|
Research and Markets: Global Opioid-Induced Constipation (OIC) Therapeutics Pipeline Review 2014 - Analysis of 11 Companies & 13 Drug Profiles
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/5qvdpr/opioidinduced)
has announced the addition of the "Opioid-Induced
Constipation (OIC) - Pipeline Review, H1 2014" report to their
offering.
This report provides comprehensive information on the therapeutic
development for Opioid-Induced Constipation (OIC), complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic
development for Opioid-Induced Constipation (OIC) and special features
on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Scope
-
The report provides a snapshot of the global therapeutic landscape of
Opioid-Induced Constipation (OIC)
-
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved in the therapeutics
development for Opioid-Induced Constipation (OIC) and enlists all
their major and minor projects
-
The report summarizes all the dormant and discontinued pipeline
projects
-
A review of the Opioid-Induced Constipation (OIC) products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
A detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Opioid-Induced Constipation (OIC) pipeline on the
basis of target, MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Companies Involved in Therapeutics Development
-
Shionogi & Co., Ltd.
-
AstraZeneca PLC
-
Cubist Pharmaceuticals, Inc.
-
Progenics Pharmaceuticals, Inc.
-
Cosmo Pharmaceuticals S.p.A
-
Theravance, Inc.
-
Sucampo Pharmaceuticals, Inc.
-
AIKO Biotechnology, Inc.
-
Synergy (News - Alert) Pharmaceuticals, Inc.
-
S.L.A. Pharma AG
-
Develco Pharma Schweiz AG
Drug Profiles
-
naloxegol
-
lubiprostone
-
methylnaltrexone bromide
-
naldemedine
-
bevenopran
-
naloxone hydrochloride PR
-
methylnaltrexone bromide
-
TD-1211
-
naloxone hydrochloride SR
-
SP-333
-
naloxone hydrochloride
-
(6-beta-naltrexol + oxycodone)
For more information visit http://www.researchandmarkets.com/research/5qvdpr/opioidinduced
[ Back To TMCnet.com's Homepage ]
|